$RGNX

Sarepta's Elevidys revenue cratered 73% to $102 million as a boxed warning and three deaths gutted the gene-therapy story

Sarepta sold investors a once-in-a-generation franchise: the first FDA-approved gene therapy for Duchenne muscular dystrophy, a $3.2-million one-time infusion, a Roche partnership for the rest of the …